

# 1 **A trimer plus a dimer-gallate reproduce the** 2 **bioactivity described for an extract of grape** 3 **seed procyanidins**

4 Authors:

5 Gemma Montagut(a,1), Isabel Baiges(a,1), Josep Valls(b), Ximena Terra(a), Josep M. del Bas(a), Xavier  
6 Vitrac(b), Tristan Richard(b), Jean-Michel Mérillon(b), Lluís Arola(a), Mayte Blay(a), Cinta Bladé(a),  
7 Juan Fernández-Larrea(a), Gerard Pujadas(a), Josepa Salvadó(a), Anna Ardévol(a,\*)

8 Affiliations:

9 (a) Department of Biochemistry and Biotechnology, Unitat d'Enologia del Centre de Referència en  
10 Tecnologia dels Aliments de la Generalitat de Catalunya, Universitat Rovira i Virgili, C.

11 Marcel·li.Domingo, s/n, 43007 Tarragona, Spain

12 (b) Groupe d'Etude des Substances Végétales à Activité Biologique, EA 3675, Université de Bordeaux 2,  
13 Bordeaux, France

14 (1) Gemma Montagut and Isabel Baiges contributed equally to this work.

15 (\*) Corresponding author: [anna.ardevol@urv.cat](mailto:anna.ardevol@urv.cat)

## 16 **ABSTRACT**

17 The relationship between grape seed-derived procyanidin extract components and their bioactivity was  
18 explored. The monomeric and dimeric structures only acted as anti-inflammatory agents. Similarly, pure  
19 C1 trimer was highly effective on LPS-activated macrophages. To reproduce all of the bioactivities of the  
20 total extract, a fraction enriched with trimeric structures was needed. This trimeric-enriched fraction was  
21 divided into subfractions, the most bioactive of which contained two compounds with a molecular weight

22 equal to a trimer (865) and a dimer-gallate (729), according to spectrometric analysis. Thus, it may be  
23 concluded that a mixture of both molecules reproduces the bioactivity in glucose metabolism (3T3-L1),  
24 lipid metabolism (HepG2) and macrophage functionality (RAW 264.6).

25 **Keywords:** Dimer-gallate, Procyanidin, Trimer, Glucose uptake, Triacylglycerol secretion, Cholesterol  
26 secretion, Anti-inflammatory effect.

## 27 **1. Introduction**

28 The "French paradox" has attracted the attention of researchers worldwide for more than a decade  
29 (Renaud & De Lorgeril, 1992). Many studies have proved several positive and healthy effects of grape  
30 seed-derived procyanidins (GSPE) (Aron & Kennedy, 2008; Rasmussen, Frederiksen, Struntze  
31 Krogholm, & Poulsen, 2005). Most of them, however, have examined phenolic extracts derived from  
32 grape seed, because they are waste products of the winery and grape juice industry—a rich source of  
33 polyphenols—and because it is difficult to find individual compounds as pure structures in these extracts.

34 The composition of GSPE is known to consist largely of gallic acid, catechin, epicatechin and  
35 procyanidin dimers and trimers composed of flavan-3-ol units with C4-C8 or C4-C6 interflavan linkages  
36 (Agarwal et al., 2007). These compounds are also present as esters linked to gallic acid in the aliphatic 3-  
37 hydroxyl group in the C ring. Some attempts have been made to evaluate how effective the different  
38 components of these extracts are at improving some of the well-described properties of the whole extract,  
39 mainly growth inhibition and apoptotic death (Agarwal et al., 2007; Faria, Calhau, deFreitas, & Mateus,  
40 2006; Lizarraga et al., 2007). Guo et al. (2007) proved that oligomeric and polymeric grape seed  
41 procyanidins are effective at protecting and treating ailments in the central nervous system induced by  
42 alcohol abuse.

43 Grape seed-derived procyanidin extracts have several healthful properties: for example, they act as  
44 antioxidants (Puiggròs et al., 2005), they improve lipid metabolism (del Bas et al., 2005), they limit

45 adipogenesis (Pinent et al., 2005), and they function as insulinomimetic agents (Pinent et al., 2004) and  
46 anti-inflammatory agents (Terra et al., 2007). This study aims to identify the structure(s) responsible for  
47 these healthful effects. This was achieved by two fractionation steps of the initial extract according to its  
48 effectiveness at improving several functions in three different cell lines. Once a highly effective fraction  
49 had been identified, its structures were characterised using HPLC-ESI-MS and the molecular weights of  
50 individual peaks were confirmed using MALDI-TOF.

## 51 **2. Materials and methods**

### 52 **2.1. Cells, reagents and materials**

53 The procyanidin extract contained 76% procyanidin with the following composition: 1.63% phenolic  
54 acids (mainly gallic acid), 20.92% monomers (mainly catechin + epicatechin), 20.71% dimers +  
55 epigallocatechin-gallate (EGCG), 17.33% trimers and 39.41% oligomeric forms of four units or more.  
56 Pure molecules were mostly obtained from SIGMA (Madrid, Spain). These were hippuric acid, ferulic  
57 acid, 3-hydroxybenzoic acid, 3,4-dihydroxyphenylacetic acid, p-hydroxyphenylacetic acid, vanillic acid,  
58 3-hydroxyphenylacetic acid, p-coumaric acid, epigallocatechin, catechin gallate, epicatechin,  
59 galocatechin gallate, epicatechin gallate, catechin hydrate and epigallocatechin gallate. Procyanidin B1–  
60 B4 came from APIN Chemicals (Abingdon, Oxon, UK). All procyanidin extracts, fractions, subfractions  
61 and pure molecules were prepared in absolute ethanol. Appropriate dilutions were made in order to obtain  
62 a 0.1% (v/v) ethanol concentration in all control and treated wells.

63 Cell culture reagents were obtained from BioWhittaker (Verviers, Belgium). Insulin (Actrapid) was from  
64 Novo Nordisk Pharma SA (Madrid, Spain). Bradford protein reagent was from Bio-Rad Laboratories  
65 (Life Science Group, Hercules, CA, USA), 2-deoxy-[1-3H]-glucose and <sup>14</sup>C-acetate was from Amersham  
66 Biosciences (Buckinghamshire, England).

### 67 **2.2. Chromatographic separation of procyanidin extract**

68 GSPE (0.5 g) was subjected to normal-phase chromatography column (35–70 mesh, Interchim,  
69 Montluçon, France) preconditioned with solvent A (acetone/hexane, 65:35) as follows: GSPE  
70 components were separated according to size using an increasing gradient of solvent B (acetone/hexane,  
71 80:20). First, low molecular weight compounds were eluted with solvent A, then the proportion of solvent  
72 B was gradually increased until it reached 100% after 1 h. Finally, an additional volume of solvent B was  
73 added, and 10 mL fractions were collected using a fraction collector. The fractions collected were  
74 monitored using TLC on PolyGram silica gel 0.2 mm with fluorescent indicator UV254 (Macherey-  
75 Nagel, Hoerd, France), with the mixture toluene/acetone/acetic acid (3:3:1, v/v/v). The TLC plates were  
76 visualised following spraying with anisaldehyde reagent. Eleven major fractions with increasing degrees  
77 of polymerisation were identified, according to their retention time,  $R_f$  (Terra et al., 2007). These  
78 fractions were vacuum-dried and kept at -20 °C for subsequent use in the biological studies.

79 The most effective fraction (VIII) was further subfractionated by semipreparative HPLC (Varian, Model  
80 210 Walnut Creek, CA, USA) with a 4 x 250 mm Ultrasep RP18 column (4  $\mu$ m) (Bischoff, Leonberg,  
81 Germany) at room temperature using the following solvents: water/formic acid (95.5:4.5, v/v) (A) and  
82 acetonitrile/solvent A (10:90, v/v) (B) with the following gradient system: 0–40% B (0–10 min), 40–60%  
83 B (10–35 min), 60–100% B (35–50 min) and 100% B (50–60 min). Detection was carried out at 286 and  
84 306 nm, with a UV–vis detector (Varian, Model 345, Walnut Creek, CA, USA).

85 An initial approach for determining molecular weight was to use HPLC-ESI-MS. A Platform II  
86 (Micromass, Manchester, UK) with electrospray injection (ESI) was used, coupled to the LC apparatus  
87 (reversed phase LC on a Waters TM system 600 E, Saint-Quentin, France). Procyanidins can easily shed  
88 a proton, generating intense negative ions  $[M-H]^-$ , so detection was performed in the negative ion mode.  
89 A low voltage was used to avoid fragmentation; the products were identified by their molecular peaks.

90 The chromatogram peaks isolated by semipreparative HPLC were also characterised by MALDI-TOF.  
91 MALDI-MS spectra were obtained using a matrix-assisted laser-desorption ionisation-time-of-flight mass

92 spectrometer (TofSpec MALDI-TOF) from Micromass (Manchester, UK). This instrument has a pulsed  
93 nitrogen laser (337 nm, 4 ns pulse width) and a time-delayed extracted ion source. Spectra were recorded  
94 in the positive-ion mode using the reflectron and a 20 kV accelerating voltage.

### 95 **2.3. Cell culture and measurements**

96 3T3-L1 preadipocytes were cultured and induced to differentiate as previously described (Ardévol, Bladé,  
97 Salvadó, & Arola, 2000). Ten days after differentiation, fully differentiated adipocytes were washed twice  
98 with phosphate buffered saline (PBS) and incubated at 37 °C with serum-free supplemented Dulbecco's  
99 modified Eagle medium (DMEM) containing 0.2% bovine serum albumin (BSA) (depletion medium) for  
100 2 h. During the last 30 min of this depletion treatment, the cells were treated with GSPE or insulin.  
101 Afterwards, glucose transport was determined by measuring the uptake of 2-deoxy-D-[3H] glucose, as  
102 previously described by Pinent et al. (2004). Each condition was run in triplicate.

103 HepG2 cells (ATCC code HB-8065, Manassas, VA, USA) were propagated in DMEM and cultured as  
104 previously described (Puiggròs et al., 2005). The only modification was the addition of 25 mM 4-(2-  
105 hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) (SIGMA, Madrid, Spain) to the culture media.  
106 For the experiments, HepG2 cells were seeded at 750,000 cell/well in 12-well-plates and left to grow for  
107 two days (80% confluence) in a propagation medium. The medium was replaced 16 h before treatment.  
108 Then, lipid synthesis was measured. Procyanidins and <sup>14</sup>C acetate (0.6 μCi/mL) were added to the cell  
109 media and 6 h after treatment the media and cells were collected and the lipids were extracted using 3  
110 volumes and 0.5 ml of hexane/isopropanol (3:2, v/v) respectively. Thin layer chromatography was  
111 performed with petroleum ether: diethyl ether: NH<sub>3</sub> (40:10:0.1) and an additional separation using a  
112 hexane/methyl tert-butyl ether (MTBE)/NH<sub>4</sub>OH (30:20:0.1, v/v/v) solvent to obtain the free cholesterol,  
113 cholesterol ester and triacylglycerol (TAG) fractions. Each fraction was scraped and determined by  
114 scintillation counting. Values were corrected per milligram of protein, determined using the Bradford  
115 methodology (Bradford, 1976). The medium was collected after 24 h treatment and apolipoprotein B was

116 detected as described in del Bas et al. (2008).

117 Murine macrophage cell line RAW 264.7 (European Tissue Culture Collection, ECACC, Ref. 91062702,  
118 London, UK) was cultured as previously described (Terra et al., 2007) and used for experiments between  
119 passages 5 and 14. At 80% of confluence, adherent monocyte-RAW 264.7 cells were incubated with  
120 different compounds and with 1 µg/mL LPS simultaneously for 19 h. The culture medium for control and  
121 treated cells was collected and tested for nitric oxide (NO) and prostaglandin E2 (PGE2) production. The  
122 nitrite concentration in the culture medium was measured as an indicator of NO production according to  
123 the Griess reaction (Terra et al., 2007). The level of PGE2 released into culture medium was quantified  
124 and normalised as previously described (Terra et al., 2007).

#### 125 **2.4. Calculations and statistical analysis**

126 Results are expressed as the mean ± SEM. Effects were assessed using Student's t-test. All calculations  
127 were performed using SPSS software.

### 128 **3. Results and discussion**

#### 129 **3.1. Monomeric and dimeric components of grape seed-derived extract act mainly as anti-** 130 **inflammatory agents**

131 The main objective of this work was to identify the molecule(s) responsible for the bioactivity of a grape  
132 seed procyanidin extract that act in vivo as (a) an antihyperglycemic (Pinent et al., 2004), (b) an  
133 antiatherogenic (del Bas et al., 2005, 2008) and (c) an anti-inflammatory (Terra et al., 2008) product. To  
134 meet this objective, three cell lines in which GSPE has been identified as being highly active, namely  
135 adipocytes (Pinent et al., 2005; Pinent, Bladé, Salvadó, Arola, & Ardévol, 2005a, 2005b), hepatocytes  
136 (del Bas et al., 2005; Puiggròs et al., 2005), and macrophage cells (Terra et al., 2007) were used. The  
137 effects that pure compounds have on these cells and the two fractionation steps have on the whole extract  
138 were evaluated.

139 The monomeric components of the extract have clearly been proven to reach body fluids and some of  
140 them have been modified in the body (Manach, Williamson, Morand, Scalbert, & Remesy, 2005). Thus,  
141 we hypothesise that these molecules or their modified forms are the main cause of the effects described.  
142 However, as Table 1 summarises, none of these pure monomeric compounds stimulated glucose uptake in  
143 the adipocytes, and HepG2 hepatocytes had no effect on TAG or total cholesterol secreted to the cell  
144 culture media while 25 mg/L GSPE inhibited TAG and TC secretion 45% and 25% respectively (results  
145 not shown). Neither did pure dimeric compounds act on the functions tested (Table 2). Both results agree  
146 with those found in the first fractionation step (Terra et al., 2007). Table 3 indicates that the fractions  
147 enriched with monomeric and dimeric compounds did not seem to affect adipocytes or hepatocytes.  
148 Monomeric components were previously reported not to induce lipolysis in adipocytes (Ardévol et al.,  
149 2000) or to protect against oxidative stress in Fao hepatocytes (Roig, Cascón, Arola, Bladé, & Salvadó,  
150 2002). In both situations the total extract was highly effective. Only fractions III and V showed a slight  
151 but significant decrease in the amount of ApoB secreted to the cell culture media of HepG2 cells. Both  
152 fractions, together with fraction IV, share a peak at the end of the chromatogram that could be epicatechin  
153 gallate. In this respect, Yee et al. (2002) also found that, unlike EC, EGCG is a potent inhibitor of ApoB  
154 secretion, suggesting that the gallate moiety has a beneficial effect on the catechin molecule and that this  
155 is beneficial for lipid metabolism in terms of ApoB secretion.

156 Also, a common trait in the different approaches was that almost all monomeric (Table 1) and dimeric  
157 (Table 2) structures showed anti-inflammatory properties equal to the total grape seed procyanidin extract  
158 (Fig. 1) and in some cases had a stronger effect (i.e., EGCG limited NO production). These results agree  
159 with previously published works showing the anti-inflammatory effect of procyanidin B2 (Chen, Cai,  
160 Kwik-Urbe, Zeng, & Zhu, 2006; Zhang et al., 2006).

### 161 **3.2. Oligomeric fractions of the extract justify its complete bioactivity**

162 Park, Rimbach, Saliou, Valacchi, and Packer (2000) have shown that trimeric procyanidin C2 do not act

163 as an anti-inflammatory compound. The trimer C1 has now been examined and it has been shown not  
164 only to have a considerable anti-inflammatory effect (Fig. 1) but also to be active on hepatocytes and  
165 adipocytes (Table 2). C1 reproduces most of the bioactive effects of the total extract. We evaluated it as a  
166 pure compound at the same concentration of the total extract and found a much lower effect (GSPE  
167 inhibited 45% TAG secretion in HepG2). However, this is the first time a C1 procyanidin has been  
168 described as having a bioactivity that is different from its antioxidant activity, which was previously  
169 shown to be higher than the antioxidant activity of other smaller oligomeric structures (da Silva Porto,  
170 Laranjinha, & de Freitas, 2003).

171 Examination of the trimeric-enriched fractions in the extract examined here showed that fractions VIII–  
172 XIII positively activate all the biological functions (see Table 3). Fraction VIII almost completely lacks  
173 monomers and dimers, but has the greatest bioactivity in the extract tested. Another fractionation step was  
174 carried out on fraction VIII to reach the objective. Fig. 2a shows a chromatogram of those subfractions  
175 whose bioactivity was closer to the total of fraction VIII (S2, S3, S4 and S12) for both cell lines. Fig. 2b–  
176 d summarises all the results obtained with these subfractions. Several bioactive subfractions (S2, S3, S4,  
177 S6, S12 and S13) can be found effective for both cell lines. However, it should be taken into account that  
178 the bioactivity of each one of these subfractions was evaluated at the same concentration as the total  
179 initial extract in each cell line. This facilitates the comparison of the effects between subfractions, but also  
180 distorts the truth because the amount of each subfraction obtained was in the order of S13 (3.6 mg) > S12  
181 > S11 > S10 > S7 > S6 > S8 > S4 > S5-S9 > S2 > S3 (0.5 mg). S12 was the biggest subfraction and it had  
182 the greatest effect, so it was selected for further analysis. Two complementary analyses were carried out:  
183 the fraction VIII was analysed with HPLC-ESI-MS and the isolated S12 subfraction with MALDI-TOF  
184 analysis. The results showed that S12 has two molecular weight components: a dimer-gallate (729) and a  
185 trimer (865), the two peaks found in the HPLC chromatogram (Fig. 2a). The trimer component has been  
186 assigned to C1 procyanidin by comparing retention times and because it is the most abundant form in  
187 grape seed (de Pascual-Teresa, Santos-Buelga, & Rivas-Gonzalo, 2000). However, the dimer-gallate is

188 probably not the B2-gallate, which was identified at S13, a fraction that did not share a single peak with  
189 S12 and which was barely active on the three assayed functions. Similarly, Schäfer and Högger (2007)  
190 have demonstrated that the inhibitory action of Pycnogenol on  $\alpha$ -glucosidase, in vitro, was stronger in  
191 extract fractions with higher procyanidin oligomers. Working with apple procyanidins, Sugiyama et al.  
192 (2007) also described an inhibitory effect on pancreatic lipase activity which depended on size. Mao, Van  
193 De Water, Keen, Schmitz, and Gershwin (2003) found that the effects on cytokine expression in  
194 peripheral blood mononuclear cells depended on the cocoa procyanidin fraction evaluated. Faria et al.  
195 (2006) showed that the simpler procyanidin structures, including catechin, have a higher antioxidant  
196 activity, which correlates with their antiproliferative effect on the cell lines of breast cancer. Agarwal et  
197 al. (2007) identified B2-3,3'-di-O-gallate as a major active constituent against growth inhibition and  
198 apoptosis, relaying most of its power to its galloyl group because B2 was barely active. Similarly,  
199 Lizarraaga et al. (2007) observed that the fractions that were most efficient at inhibiting cell proliferation,  
200 arresting the cell cycle in the G(2) phase and inducing apoptosis, were the grape fractions with the highest  
201 percentage of galloylation and mean degree of polymerisation.

202 All these results together will be very helpful for understanding some of the differential and/or sometimes  
203 contradictory effects described for complete extracts of natural origin. Simple procyanidin structures have  
204 higher antioxidant properties. Short structures with higher galloylation seem to be more active as  
205 antiproliferatives. At least one trimer and one dimer-gallate are needed to have metabolic effects.

#### 206 **4. Conclusions**

207 Monomeric structures and dimers (mainly fraction VI) of grape seed extract were the only effective as  
208 anti-inflammatory agents. Procyanidin C1 was also very active as an anti-inflammatory compound.  
209 Subfraction 12 was the most effective in all the parameters examined. As HPLC-ESI-MS and MALDI-  
210 TOF analysis showed, this fraction contains a trimer (865) and a dimer-gallate (729). Therefore, a mix of  
211 both molecules reproduces the bioactivity in glucose metabolism, lipid metabolism and macrophage

212 functionality which has previously been described for the total grape seed extract.

## 213 **Acknowledgments**

214 We thank Christian Brassington and John Bates for the English correction of the manuscript. This study  
215 was supported by Grant Number AGL2005-04889/ALI from the Comisión Interministerial de Ciencia y  
216 Tecnología (CICYT) of the Spanish Government. Gemma Montagut and Ximena Terra are recipients of  
217 fellowships from the Rovira i Virgili University in Tarragona, Spain. Josep M. del Bas was a recipient of  
218 a fellowship from Comisión Interministerial de Ciencia y Tecnología (CICYT) of the Spanish  
219 Government.

## 220 **References**

221 Agarwal, C., Veluri, R., Kaur, M., Chou, S., Thompson, J., & Agarwal, R. (2007). Fractionation of high  
222 molecular weight tannins in grape seed extract and identification of procyanidin B2-3,3'-di-O-gallate as a  
223 major active constituent causing growth inhibition and apoptotic death of DU145 human prostate  
224 carcinoma cells. *Carcinogenesis*, 28(7), 1478-1484.

225 Ardévol, A., Bladé, C., Salvadó, M. J., & Arola, L. (2000). Changes in lipolysis and hormone-sensitive  
226 lipase expression caused by procyanidins in 3T3-L1 adipocytes. *International Journal of Obesity and  
227 Related Metabolic Disorders: Journal of the International Association for the Study of Obesity*, 24, 319-  
228 324.

229 Aron, P. M., & Kennedy, J. A. (2008). Flavan-3-ols: Nature, occurrence and biological activity.  
230 *Molecular Nutrition and Food Research*, 52(1), 79-104.

231 Bradford, M. M. (1976). A rapid and sensitive method for quantitation of microgram quantities of protein  
232 utilizing the principle of protein-dye binding. *Analytical Biochemistry*, 72, 248-254.

233 Chen, D., Cai, X., Kwik-Urbe, C. L., Zeng, R., & Zhu, X. (2006). Inhibitory effects of procyanidin B2

234 dimer on lipid-laden macrophage formation. *Journal of Cardiovascular Pharmacology*, 48(2), 54-70.

235 da Silva Porto, P. A., Laranjinha, J. A., & de Freitas, V. (2003). Antioxidant protection of low density  
236 lipoprotein by procyanidins: Structure/activity relationships. *Biochemical Pharmacology*, 66(6), 947-954.

237 de Pascual-Teresa, S., Santos-Buelga, C., & Rivas-Gonzalo, J. C. (2000). Quantitative analysis of flavan-  
238 3-ols in Spanish foodstuffs and beverages. *Journal of Agricultural and Food Chemistry*, 48(11), 5331-  
239 5337.

240 Del Bas, J. M., Fernandez-Larrea, J., Blay, M., Ardevol, A., Salvado, M. J., Arola, L., et al. (2005). Grape  
241 seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in  
242 healthy rats. *FASEB Journal*, 19(3), 479-481.

243 Del Bas, J. M., Ricketts, M. L., Baiges, I., Quesada, H., Ardevol, A., Salvadó, M. J., et al. (2008). Dietary  
244 procyanidins lower triglyceride levels signaling through the nuclear receptor small heterodimer partner.  
245 *Molecular Nutrition and Food Research*, 52(10), 1172-1181.

246 Faria, A., Calhau, C., deFreitas, V., & Mateus, N. (2006). Procyanidins as antioxidants and tumor cell  
247 growth modulators. *Journal of Agricultural and Food Chemistry*. 54(6), 2392-2397.

248 Guo, L., Wang, L. H., Sun, B., Yang, J. Y., Zhao, Y. Q., Dong, Y. X., et al. (2007). Direct in vivo  
249 evidence of protective effects of grape seed procyanidin fractions and other antioxidants against ethanol-  
250 induced oxidative DNA damage in mouse brain cells. *Journal of Agricultural and Food Chemistry*,  
251 55(14), 5881-5891.

252 Lizarraga, D., Lozano, C., Briede, J. J., van Delft, J. H., Tourino, S., Centelles, J. J., et al. (2007). The  
253 importance of polymerization and galloylation for the antiproliferative properties of procyanidin-rich  
254 natural extracts. *FEBS Journal*. 274(18), 4802-4811.

255 Manach, C., Williamson, G., Morand, C., Scalbert, A., & Remesy, C. (2005). Bioavailability and

256 bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *American Journal of*  
257 *Clinical Nutrition*, 81(1), 230S-242S.

258 Mao, T. K., Van De Water, J., Keen, C. L., Schmitz, H. H., & Gershwin, M. E. (2003). Cocoa flavonols  
259 and procyanidins promote transforming growth factor-(beta)1 homeostasis in peripheral blood  
260 mononuclear cells. *Experimental Biology and Medicine*, 228(1), 93-99.

261 Park, Y. C., Rimbach, G., Saliou, C., Valacchi, G., & Packer, L. (2000). Activity of monomeric, dimeric,  
262 and trimeric flavonoids on NO production, TNF- $\alpha$  secretion, and NF- $\kappa$ B-dependent gene expression in  
263 RAW 264.7 macrophages. *FEBS Letters*, 465(2-3), 93-97.

264 Pinent, M., Bladé, M., Salvadó, M., Arola, L., & Ardévol, A. (2005a). Metabolic fate of glucose on 3T3-  
265 L1 adipocytes treated with grape seed-derived procyanidin extract (GSPE), Comparison with the effects  
266 of insulin. *Journal of Agricultural and Food Chemistry*, 53(15), 5932-5935.

267 Pinent, M., Bladé, M. C., Salvadó, M. J., Arola, L., & Ardévol, A. (2005b). Intracellular mediators of  
268 procyanidin-induced lipolysis in 3T3-L1 adipocytes. *Journal of Agricultural and Food Chemistry*, 53,  
269 262-266.

270 Pinent, M., Blade, M. C., Salvado, M. J., Arola, L., Hackl, H., Quackenbush, J., et al. (2005). Grape-seed  
271 derived procyanidins interfere with adipogenesis of 3T3-L1 cells at the onset of differentiation.  
272 *International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association*  
273 *for the Study of Obesity*, 29(8), 934-941.

274 Pinent, M., Blay, M., Blade, M. C., Salvado, M. J., Arola, L., & Ardevol, A. (2004). Grape seed-derived  
275 procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and  
276 insulinomimetic activity in insulin-sensitive cell lines. *Endocrinology*, 145(11), 4985-4990.

277 Puiggròs, F., Llopiz, N., Ardevol, A., Blade, C., Arola, L., & Salvado, M. J. (2005). Grape seed

278 procyanidins prevent oxidative injury by modulating the expression of antioxidant enzyme systems.  
279 *Journal of Agricultural and Food Chemistry*, 53(15), 6080-6086.

280 Rasmussen, S., Frederiksen, H., Struntze Krogholm, K., & Poulsen, L. (2005). Dietary  
281 proanthocyanidins: Occurrence, dietary intake, bioavailability, and protection against cardiovascular  
282 disease. *Molecular Nutrition and Food Research*, 49(2), 159-174.

283 Renaud, S., & De Lorgeril, M. (1992). Vin, alcool, plaquettes et coronaropathies: Le paradoxe français.  
284 *Lancet*, 225, 22-25 (French ed.).

285 Roig, R., Cascón, E., Arola, L., Bladé, C., & Salvadó, M. J. (2002). Procyanidins protect Fao cells against  
286 hydrogen peroxide-induced oxidative stress. *Biochimica et Biophysica Acta (BBA) General Subjects*,  
287 1572(1), 25-30.

288 Schäfer, A., & Högger, P. (2007). Oligomeric procyanidins of French maritime pine bark extract  
289 (Pycnogenol) effectively inhibit  $\alpha$ -glucosidase. *Diabetes Research and Clinical Practice*, 77(1), 41-46.

290 Sugiyama, H., Akazome, Y., Shoji, T., Yamaguchi, A., Yasue, M., Kanda, T., et al. (2007). Oligomeric  
291 procyanidins in apple polyphenol are main active components for inhibition of pancreatic lipase and  
292 triglyceride absorption. *Journal of Agricultural and Food Chemistry*, 55(11), 4604-4609.

293 Terra, X., Montagut, G., Bustos, M., Llopiz, N., Ardevol, A., Blade, C., et al. (2008). Grape-seed  
294 procyanidins prevent low-grade inflammation by modulating cytokine expression in rats fed a high-fat  
295 diet. *The Journal of Nutritional Biochemistry*. Epub ahead of print. doi: 10.1016/j.jnutbio.2008.02.005.

296 Terra, X., Valls, J., Vitrac, X., Merrillon, J. M., Arola, L., Ardevol, A., et al. (2007). Grape-seed  
297 procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by  
298 inhibiting NF $\kappa$ B signaling pathway. *Journal of Agricultural and Food Chemistry*, 55(11), 4357-4365.

299 Yee, W., Wang, Q., Agdinaoay, T., Dang, K., Chang, H., Grandinetti, A., et al. (2002). Green tea

300 catechins decrease apolipoprotein B-100 secretion from HepG2 cells. *Molecular and cellular*  
301 *biochemistry*, 229(1-2), 85-92.

302 Zhang, W., Liu, H., Xie, K., Yin, L., Li, Y., Kwik-Urbe, C. L., et al. (2006). Procyanidin dimer B2  
303 [epicatechin-(4-8)-epicatechin suppresses the expression of cyclooxygenase-2 in endotoxin-treated  
304 monocytic cells. *Biochemical and Biophysical Research Communications*, 345(1), 508-515.

## 305 **Figure Captions**

306 **Fig. 1.** Inhibition of PGE2 and NO production by C1 in LPS induced RAW 264.7 macrophages. RAW  
307 264.7 macrophages were simultaneously stimulated with LPS for 19 h and incubated with C1 (trimeric  
308 procyanidin) at 5 mg/L and GSPE (grape seed procyanidin extract) at 45 mg/L as reference. PGE2 and  
309 NO production were measured after treatment. Results were normalised to control levels ( $100.0\% \pm 6.2$ ).  
310 Each bar represents mean  $\pm$  SEM of nine biological experiments. Different letters mean  $p < 0.05$  as  
311 compared to GSPE treatment.

312 **Fig. 2.** Results from the second fractionation step. (a) Chromatograms of the most active subfractions. In  
313 correlative order: S2, S3, S4 and S12. (b) Stimulation of glucose uptake done by each of the subfractions  
314 obtained. After 2 h of depletion, differentiated 3T3-L1 adipocytes were treated for 30 min with 100 mg/L  
315 of total fraction VIII or each subfraction. Afterwards, glucose uptake was measured. Results are related to  
316 the maximum stimulation achieved by insulin ( $1.037 \pm 0.023$ ). (c and d) Effect of fraction VIII and its  
317 subfractions in de novo synthesised triacylglycerols (c) and total cholesterol (d) secretion to the  
318 extracellular media. HepG2 cultures were incubated for 6 h with fraction VIII or its subfractions at 25  
319 mg/L and  $^{14}\text{C}$ -acetate. Afterwards, lipid fractions secreted to the cell culture media were quantified.  
320 Media lipid fraction levels (dpm/mg protein) were normalised to the control levels set at one. Each bar  
321 represents mean  $\pm$  SEM. Letters above the bars mean  $p < 0.05$  as compared to control. Different letters  
322 mean  $p < 0.05$  as compared to fraction VIII treatment.

323 **Tables**

324 Table 1

325 Summary of the bioactivity of the monomeric pure forms. Values in italics mean a statistically significant  
 326 positive effect ( $p < 0.05$ ).

<b>Monomeric structures</b>	<b>Stimulation of glucose uptake (3T3-L1 adipocytes) 150 mg/L compound (stimulation vs insulin effect <math>1.04 \pm 0.023</math>)</b>	<b>PGE-2 production (RAW macrophages) 5 mg/L compound (% of inhibition vs LPS stimulation <math>100.0 \pm 1.2</math>)</b>	<b>NO production RAW macrophages 5 mg/L compound (% of inhibition vs LPS stimulation <math>100.0 \pm 6.2</math>)</b>
Vanillic acid	$0.055 \pm 0.018$	<i><math>60.63 \pm 9.61</math></i>	<i><math>69.69 \pm 0.56</math></i>
Epicatechin	$0.024 \pm 0.014$	<i><math>46.73 \pm 0.73</math></i>	<i><math>64.77 \pm 0.70</math></i>
Epicatechin gallate	NA	<i><math>48.18 \pm 6.66</math></i>	<i><math>32.87 \pm 8.72</math></i>
EGCG	NA	<i><math>53.72 \pm 5.63</math></i>	<i><math>6.67 \pm 3.56</math></i>
Catechin	$0.051 \pm 0.018$	<i><math>57.98 \pm 5.99</math></i>	$103.7 \pm 1.35$
Gallic acid	$0.048 \pm 0.010$	<i><math>46.63 \pm 2.51</math></i>	<i><math>93.4 \pm 0.8</math></i>
p-Hydroxyphenylacetic acid	$0.054 \pm 0.014$	<i><math>55.31 \pm 4.00</math></i>	$111.79 \pm 5.28$

p-Coumaric	0.058 ± 0.020	NA	NA
3-Hydroxybenzoic acid	0.058 ± 0.008	NA	NA
Protocatequic acid	0.073 ± 0.049	NA	NA
Ferulic acid	0.092 ± 0.068	NA	NA
Hippuric acid	0.085 ± 0.047	NA	NA

327 Table 2

328 Summary of the bioactivity of the oligomeric pure compounds. Values in italics mean a statistically  
329 significant positive effect ( $p < 0.05$ ).

<b>Oligomeric pure structures</b>	<b>Stimulation of glucose uptake 150 mg/L compound (stimulation vs insulin effect 1.037 ± 0.023)</b>	<b>PGE-2 production 5 mg/L compound (% of inhibition vs LPS stimulation 100.0 ± 1.2)</b>	<b>NO production 5 mg/L compound (% of inhibition vs LPS stimulation 100.0 ± 6.2)</b>	<b>Total cholesterol secretion 25 mg/L compound (fold change vs control 1.00 ± 0.02)</b>	<b>Triacylglycerol secretion 25 mg/L compound (fold change vs control 1.01 ± 0.01)</b>
B3	0.09 ± 0.02	<i>69.92 ± 11.14</i>	<i>83.98 ± 4.56</i>	1.26 ± 0.16	1.18 ± 0.11

B1	0.08 ± 0.07	<i>70.78 ± 15.8</i>	<i>42.56 ± 3.52</i>	1.29 ± 0.12	1.05 ± 0.11
B2	0.09 ± 0.05	<i>79.86 ± 0.17</i>	<i>60.12 ± 7.49</i>	1.15 ± 0.11	1.07 ± 0.09
B4	0.07 ± 0.03	<i>68.92 ± 0.04</i>	<i>46.58 ± 3.90</i>	1.22 ± 0.13	1.20 ± 0.16
C1	<i>0.13 ± 0.00</i> (100 mg/L)	<i>44.38 ± 1.42</i>	<i>20.96 ± 5.85</i>	1.05 ± 0.11	<i>0.82 ± 0.04</i>

330 Table 3

331 Summary of the bioactivity of the fractions obtained from the grape seed-derived extract. Values in italics  
332 mean a statistically significant positive effect ( $p < 0.05$ ). In the first column, the intensity of the shade of  
333 grey correlates to the increasing degree of polymerisation.


<b>GSPE fractions (amount obtained)</b>	<b>Stimulation glucose uptake 150 mg/L compound (vs insulin effect 1.04 ± 0.02)</b>	<b>PGE-2 production 5 mg/L compound (% of inhibition vs LPS stimulation 100.0 ± 1.2)</b>	<b>NO production 5 mg/L compound (% of inhibition vs LPS stimulation 100.0 ± 6.2)</b>	<b>Triacylglycerol secretion 25 mg/L compound (fold change vs control 1.01 ± 0.01)</b>	<b>Total cholesterol secretion 25 mg/L compound (fold change vs control 1.0 ± 0.02)</b>	<b>ApoB protein secretion 10 mg/L compound (vs control 100.3 ± 0.3)</b>
I (25 mg)	-0.04 ± 0.01	NA	NA	1.07 ± 0.07	0.96 ± 0.06	NA

II (66 mg)	-0.05 ± 0.01	NA	NA	1.01 ± 0.12	1.03 ± 0.10	80.0 ± 12.8
III (6 mg)	-0.04 ± 0.02	NA	NA	0.95 ± 0.09	0.87 ± 0.08	81.0 ± 3.9
IV (4.5 mg)	-0.09 ± 0.09	51.91 ± 17.74	51.24 ± 14.63	0.85 ± 0.07	0.82 ± 0.05	NA
V (11.5 mg)	-0.02 ± 0.09	NA	52.56 ± 9.67	0.96 ± 0.06	1.03 ± 0.12	78.5 ± 1.4
VI (26 mg)	0.11 ± 0.03	63.35 ± 14.12	23.03 ± 9.05	0.83 ± 0.05	0.97 ± 0.11	79.3 ± 9.1
VII (18 mg)	0.40 ± 0.03	NA	44.60 ± 8.39	0.43 ± 0.08	0.71 ± 0.18	NA
VIII (33 mg)	0.49 ± 0.02	NA	20.52 ± 5.85	0.36 ± 0.03	0.59 ± 0.05	46.0 ± 4.9
X (23 mg)	0.35 ± 0.04	63.34 ± 11.59	23.22 ± 5.76	0.32 ± 0.01	0.58 ± 0.06	NA
XI (16 mg)	0.40 ± 0.04	NA	48.73 ± 0.77	0.41 ± 0.05	0.77 ± 0.01	NA
XII (15 mg)	NA	NA	22.48 ± 5.67	0.36 ± 0.03	0.81 ± 0.03	NA

XIII (75.4 mg)	NA	53.85 ± 10.57	22.58 ± 3.96	0.45 ± 0.00	0.72 ± 0.03	NA
XIV (81.6 mg)	NA	NA	49.44 ± 1.90	0.34 ± 0.01	0.68 ± 0.06	NA
XV (33.5 mg)	NA	NA	26.58 ± 4.13	0.45 ± 0.03	0.77 ± 0.06	NA

334 **Figures**

335 Figure 1



336

337 Figure 2

